Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers
Authors:
- Snigdha BanerjeeSBSnigdha Banerjee
- Affan A. AnsariAAAffan A. Ansari
- Sunil P. UpadhyaySUSunil P. Upadhyay
- Daniel J. MettmanDMDaniel J. Mettman
- Jamie R. HibdonJHJamie R. Hibdon
- Mohiuddin QuadirMQMohiuddin Quadir
- Pratyusha GhoshPGPratyusha Ghosh
- Anjali KambhampatiAKAnjali Kambhampati
- Sushanta K. BanerjeeSBSushanta K. Banerjee
Open Access
Abstract
The aberrant glycosylation is a hallmark of cancer progression and chemoresistance. It is also an immune therapeutic target for various cancers. Tunicamycin (TM) is one of the potent nucleoside antibiotics and an inhibitor of aberrant glycosylation in various cancer cells, including breast cancer, gastric cancer, and pancreatic cancer, parallel with the inhibition of cancer cell growth and progression of tumors. Like chemotherapies such as doxorubicin (DOX), 5′fluorouracil, etoposide, and cisplatin, TM induces the unfolded protein response (UPR) by blocking aberrant glycosylation. Consequently, stress is induced in the endoplasmic reticulum (ER) that promotes apoptosis. TM can thus be considered a potent antitumor drug in various cancers and may promote chemosensitivity. However, its lack of cell-type-specific cytotoxicity impedes its anticancer efficacy. In this review, we focus on recent advances in our understanding of the benefits and pitfalls of TM therapies in various cancers, including breast, colon, and pancreatic cancers, and discuss the mechanisms identified by which TM functions. Finally, we discuss the potential use of nano-based drug delivery systems to overcome non-specific toxicity and enhance the therapeutic efficacy of TM as a targeted therapy.Keywords
All Related Versions
Funding Information
- VA Merit Review grants (S.K.B. and S.B.) VA Research Career Award Fund (S.K.B.) (1P20 GM109024)
- National Institute of General Medical Sciences (NIGMS) (M.Q.) (1P20 GM109024)
This publication has 150 references indexed in Scilit:
- Size‐Dependent Penetration of Nanoparticles in Tumor Spheroids: A Multidimensional and Quantitative Study of Transcellular and Paracellular PathwaysSmall, 2023
- Functional siRNA Delivery by Extracellular Vesicle–Liposome Hybrid NanoparticlesAdvanced Healthcare Materials, 2021
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- ER stress‐related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancerMolecular Oncology, 2018
- Nanoparticles in the clinicBioengineering & Translational Medicine, 2016
- Role of endoplasmic reticulum stress in drug‐induced toxicityPharmacology Research & Perspectives, 2016
- N‐glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cellsJournal of Cellular Biochemistry, 2012
- A review of the mammalian unfolded protein responseBiotechnology and Bioengineering, 2011
- Matrix metalloproteinases in tumor invasion and metastasisSeminars in Cancer Biology, 2000
- Specific Toxicity of Tunicamycin in Induction of Programmed Cell Death of Sympathetic NeuronsExperimental Neurology, 1996